Table 1.
Characteristics of the included prospective case-control studies.
| Study | Journal | Study Design | Center/Country | Group R (n) | Group N (n) | Age | Sugammadex Dose | NMB Monitoring |
|---|---|---|---|---|---|---|---|---|
| de Souza et al., 2015 [11] | European Journal of Anaesthe-siology | Prospective clinical trial | Two hospitals Brazil, and Spain | ClCr < 30 mL min−1 (20) |
ClCr > 90 mL min−1 (20) |
18–65 | 4 mg kg−1 | Acceleromyography at the adductor pollicis muscle |
| Panhuizen et al., 2015 [12] | British Journal of Anaesthesia | Case control comparative study | Eight centers in Europe | ClCr < 30 mL min−1 (35) |
ClCr ≥ 80 mL min−1 (35) |
≥18 | 4 mg kg−1 | Acceleromyography at the adductor pollicis muscle |
| Staals et al., 2008 [13] |
British Journal of Anaesthesia | Prospective clinical trial | Three centers in Europe | ClCr < 30 mL min−1 (15) |
ClCr ≥ 80 mL min−1 (15) |
≥18 | 2 mg kg−1 | Acceleromyography at the adductor pollicis muscle |
| Staals et al., 2010 [2] |
British Journal of Anaesthesia | Prospective clinical trial | Three centers in Europe | ClCr < 30 mL min−1 (15) |
ClCr ≥ 80 mL min−1 (15) |
≥18 | 2 mg kg−1 | Acceleromyography at the adductor pollicis muscle |
| Maeyama et al., 2014 [14] | European Journal of Anaesthesiology | Prospective clinical trial | University hospital, Japan | ClCr < 15mL min−1 (13) |
ClCr > 90 mL min−1 (14) |
≥18 | 4 mg kg−1 | Not mentioned |
| Min et al., 2017 [15] |
International Journal of Clinical Pharmacology and Therapeutics | Open label, two parts, phase 1 study | Clinical pharma-cology of Miami, USA | ClCr < 30 mL min−1 (6) |
ClCr ≥ 80 mL min−1 (6) |
≥18 | 4 mg kg−1 | None |
R: patients with end-stage renal disease; Group N: patients with normal renal function; NMB: neuromuscular blockade; ClCr: Creatinine clearance.